All In MedTech

Device Trial Radar · NCT07671950

Neuropathic Dental Pain & DBS

Pain Alleviation for Patients Receiving Directional Deep Brain Stimulation to Treat Neuropathic Dental Pain

Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

5

Planned (sponsor's estimate)

Start

Jan 1, 2026

Primary completion

Jan 1, 2027

Study completion Jan 1, 2028

Sponsor

Lead sponsor
University of British ColumbiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 26, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 19 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective observational study will evaluate pain outcomes in patients with neuropathic dental pain (Atypical Odontalgia/Phantom Tooth Pain) who undergo directional deep brain stimulation (DBS). Participants will complete validated pain, disability, quality-of-life, and mood assessments before surgery and following DBS programming. Directional stimulation will be applied to different thalamic targets to determine whether specific stimulation settings are associated with greater pain relief. The study aims to characterize changes in pain and quality of life following DBS and to identify the stimulation target associated with the greatest reduction in neuropathic dental pain.

Conditions

  • Dental Neuralgia
  • Neuropathic Dental Pain

Interventions

  • Directional Deep Brain StimulationDevice

    Participants will receive standard-of-care directional deep brain stimulation (DBS) using an implanted DBS system. Stimulation will be delivered using ring-mode stimulation, directional stimulation toward the ventral posteromedial nucleus (VPM), anterior pulvinar (aPu), or centromedian nucleus (CM), or with stimulation turned off. Participants will undergo each stimulation condition in a randomized sequence.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain Severity Measured by Visual Analogue Scale (VAS)Time frame: Baseline (pre-operative); after each 2-week stimulation period during the 10-week post-activation programming phase; and 3 months after completion of the randomized stimulation period.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Vancouver General Hospital

    Vancouver, British Columbia, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.